Netherlands Lung Cancer Therapeutics Market Report 2022 to 2030

Netherlands Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Netherlands Lung Cancer Therapeutics Market will reach a value of $155 Mn from $77 Mn in 2022, growing at a CAGR of 8.6% during 2022-2030. The Lung Cancer Therapeutics Market in the Netherlands is dominated by a few domestic pharmaceutical companies such as Cristal Therapeutics, ISA Pharmaceuticals, and Merus. The Lung Cancer Therapeutics Market in the Netherlands is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Netherlands lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10NLPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Vishwa Modhia

Buy Now

Netherlands Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Netherlands Lung Cancer Therapeutics market will reach a value of $155 Mn from $77 Mn in 2022, growing at a CAGR of 8.6% during 2022-2030.

The Netherlands is a high-income, developed constituent country located in Western Europe and with territories in the Caribbean. There are 79 hospitals (in all, 109 locations), with seven of them being university medical centres, one being a cancer centre, and the rest being large teaching hospitals. The population-based Dutch cancer registry collects information on all patients newly diagnosed with cancer in the Netherlands. The Dutch government is devoted to the programme "smoke-free initiative."

According to the latest WHO data published in 2020 Lung Cancers Deaths in the Netherlands reached 10,980 or 8.66% of total deaths. The age-adjusted Death Rate is 29.85 per 100,000 population ranking the Netherlands #13 in the world. Netherlands' government spends 11.1% of its GDP on healthcare.

Netherlands Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

According to Dutch guidelines, all newly diagnosed lung cancer patients must be discussed in multidisciplinary tumour boards for staging and therapy recommendations. The goal is for no one to start smoking by 2040. Several strategies have been implemented to achieve this goal. A total of 2384 NSCLC resections were performed in 2019. The Netherlands has 19 radiation oncology centres, three of which are operating proton treatment facilities. However, if palliative care specialists are required, there are 14 ESMO-designed integrated cancer and palliative care centres (with this number, the Netherlands ranks fourth in Europe). The improved infrastructure and living standards in the Netherlands are a plus. These aspects could boost the Netherlands Lung Cancer Therapeutics market.

Market Restraints

Lung cancer screening is not now a standard of care in the Netherlands. As the population ages, the Dutch pension system is under strain. The frequency of robotic-assisted thoracic surgery operations is not increasing, which could be explained in part by the related financial expenditures per procedure and the lack of proof of superiority compared to VATS. Numerous hurdles lie ahead, including the growing requirement to justify reimbursement for novel therapies and diagnostic tests, the continuation of smoke-free policies, and the need to obtain legislation to begin lung cancer screening. These factors may deter new entrants into the Netherlands Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Merus: Merus N.V. is a Dutch biotechnology company that focuses on the development of innovative therapies for cancer. The company is currently developing several bispecific antibodies for the treatment of lung cancer
ISA Pharmaceuticals: ISA Pharmaceuticals B.V. is a Dutch biopharmaceutical company that specializes in the development of immunotherapies for cancer. The company is currently developing a therapeutic vaccine for the treatment of lung cancer
Cristal Therapeutics: Cristal Therapeutics B.V. is a Dutch biopharmaceutical company that focuses on the development of nanomedicines for the treatment of cancer. The company is currently developing a nanomedicine-based therapy for the treatment of lung cancer
DCprime: DCprime is a Dutch biotechnology company that specializes in the development of immunotherapies for cancer. The company is currently developing a dendritic cell-based therapy for the treatment of lung cancer

Recent Notable Updates

August 2022: In the run-up to the implementation of mass screening for lung cancer, the Netherlands is taking part in a Europe-wide lung cancer screening trial. The first of around 400,000 persons aged 60 to 79 who are or were heavy smokers will be encouraged to come in for a CT scan in the following days and weeks. According to a Dutch-Belgian study, this instrument is efficient at detecting lung cancer in its early stages.

Healthcare Policies and Reimbursement Scenarios

In the Netherlands, the regulatory authority responsible for the approval and regulation of therapeutic products, including lung cancer therapeutics, is the Medicines Evaluation Board (MEB). The Dutch national health insurance system is founded on a universal healthcare concept, which means that every resident, regardless of ability to pay, has access to healthcare services, including cancer treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.